Innovative Product Launch Darmiyan recently launched the FDA-approved BrainSee Platform, offering a cutting-edge solution for brain health assessment and Alzheimer's prognosis, indicating a strong value proposition for healthcare providers seeking advanced diagnostic tools.

Healthcare Industry Focus With a primary focus on brain diagnostics and monitoring, Darmiyan serves medical institutions and physicians, presenting opportunities to establish partnerships with hospitals, clinics, and specialty care centers dedicated to neurodegenerative disease management.

Funding and Growth Potential Having secured over $11 million in funding, including recent investments from pharma players like Eisai, Darmiyan demonstrates financial stability and potential for product expansion, which can facilitate outreach to larger healthcare providers and research institutions.

Market Positioning Competing with similar neuro-diagnostic tech firms and with revenue estimates between $10M and $25M, Darmiyan is positioned as an innovative player in the brain health space, making it an attractive partner for enterprises seeking growth in neurodiagnostic solutions.

Technology Adoption Utilizing a tech stack that integrates FDA approval with scalable AI-powered diagnostics, Darmiyan offers a compelling opportunity for institutions interested in adopting advanced, clinically validated brain screening technologies to enhance patient outcomes.